摘要
目的探讨不同时期阿霉素肾病大鼠尿液中Fractalkine表达的变化及白介素18结合蛋白(IL-18BP)的治疗作用。方法建立阿霉素肾病大鼠模型,设立肾病组(n=12)、IL-18BP干预组(n=11)和对照组(n=10)。观察42 d,定期检测大鼠尿Fractalkine水平及24 h尿蛋白定量。结果肾病组和IL-18BP干预组大鼠尿Fractalkine水平均进行性提高,差异有统计学意义(F=91.395、47.248,P均<0.01);IL-18BP干预组大鼠各时间点尿Fractalkine水平均低于肾病组(P均<0.05),高于对照组(P均<0.01)。肾病组、IL-18BP干预组大鼠尿Fractalkine水平与24 h尿蛋白定量均呈正相关(r=0.970、0.904,P均<0.01)。结论 Fractalkine与阿霉素肾病大鼠蛋白尿相关,IL-18BP可降低Fractalkine水平,可能有助于微小病变肾病治疗。
Objective To investigate the changes in Fractalkine expression in urine of adriamycin nephropathy rats at different times, and the therapeutic effect of interleukin-18 binding protein. Methods Adriamycin rat model was created, and nephropathy group （n = 12）, IL-18BP treatment group （n = 11） and normal control group （n = 10） were set up. Orinary Fractalkine levels in rat urine and 2g-hour urinary protein were regularly detected in 42 days. Results Orinary Fractalkine levels in nephropathy group and IL-18BP treatment group were gradually increased and the difference was statistically significant （F = 91.395, 47.248, P 〈 0.01） ; during the treatment period, Orinary Fractalkine levels in IL-18BP treated group were significantly lower than that in nephropathy group （P 〈 0.05）, but was significantly higher than the normal control group （P 〈 0.01 ）. Urinary Fractalkine levels was significantly positively correlated with 24-hour urinary protein （r = 0.970, P 〈 0.01）. Conclusions Fractalkine levels were correlated with protein- uria in rats with adriamycin nephropathy. IL-18BP can reduce the Fractalkine level, and thus may contribute to thetreatment of minimal change nephropathy.
出处
《临床儿科杂志》
CAS
CSCD
北大核心
2012年第7期666-669,共4页
Journal of Clinical Pediatrics
基金
佳木斯大学研究生创新科研项目(No.YJSCX2011-016JD)
